Sat 6/6/2020 06:25 ET
DJIA27110.98854.003.15%TELCO176.673.341.89%GOLD1731.6018.351.06%Shanghai2930.8011.720.40%
S&P 5003193.9383.682.62%BANKS394.7319.785.01%OIL35.341.634.61%BITCOIN9616.8724.040.25%
NASDAQ9814.08202.172.06%PHARM611.471.770.29%US/EU1.130.010.46%Futures3185.251.590.05%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Wall Street Pit (Editas Medicine, Inc - EDIT)    Stock Due Diligence for All

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add EDIT
  
From: UpAndAway (Rep: 27)Date: 04/30/2019 09:17
Forum: Wall Street Pit - Msg #2784757 - List EDIT msgs Thread #674079013 (Rec: 0)
Allergan and Editas Medicine Announce Initial Data from Natural History Study to Evaluate Patients with Leber Congenital Amaurosis 10 (LCA10)

AGN-151587 is set to be the first in vivo, or inside the body, CRISPR-based medicine administered to people anywhere in the world. In the planned Phase 1/2 clinical trial, Allergan and Editas Medicine intend to initiate patient screening mid-year and begin patient dosing in the second half of 2019, enrolling 10-20 patients in the U.S. and Europe.

Sent from my IPhone

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser UpAndAway: Reward | Watch | IgnoreEDIT: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add EDIT
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.